Three-Drug Regimen Treats Cystic Fibrosis in Younger Children

WEDNESDAY, April 14, 2021 -- The safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) for the treatment of cystic fibrosis with at least one F508del-CFTR allele in children aged 6 to 11 years are consistent with the results reported...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news